Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Focused on cost and process efficiencies, we deliver innovative technologies and solutions that help set new standards in bioprocessing.

OFFICERS

Tony Hunt, Repligen CEO

Tony J. Hunt was named President and Chief Executive Officer of Repligen in  May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management.

Jon Snodgres, Repligen CFO

Jon K. Snodgres joined Repligen in July 2014 as Chief Financial Officer, where he oversees financial operations for the company. Mr. Snodgres was previously with Maquet Cardiovascular, a medical device company where he held the CFO position for five years. At Maquet, in addition to P&L, balance sheet and cash flow responsibility, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a Bachelor of Science degree in Business Administration, Finance from Northern Arizona University.

Howard Benjamin, VP Business Development

Howard Benjamin, Ph.D. has served as Vice President, Business Development since joining Repligen in January 2009. Previously,  Mr. Benjamin worked at translational medicine start-ups Leap Technology from March 2007 to December 2008 and Growth Point Sciences from August 2005 to December 2006 in various roles including Vice President, Research and Development. From January 2000 to August 2005, Mr. Benjamin was Vice President, Corporate Development at Daiichi Asubio Medical Research Laboratories and from 1994 to 2000, Mr. Benjamin was Vice President, Discovery Research at Praecis Pharmaceuticals. Mr. Benjamin holds an S.B. in Biology from M.I.T. and a Ph.D. in Molecular Biology from University of California, Berkeley.

FUNCTIONAL LEADERS

John Connors joined Repligen in December 2016 as Vice President with responsibility for the TangenX business in Shrewsbury, MA.  Mr. Connors was previously President of TangenX Technology Corporation, a company he founded in 2004 to develop and manufacture industry leading tangential flow filtration (TFF) products.  While at TangenX, Mr. Connors and his team were responsible for bringing the first purpose-built single-use TFF cassette to the market.  Mr. Connors has spent the last twenty-three years working in the bioprocess and life science industries, first with Pall Filtron, then with Becton Dickinson and TangenX.  Throughout his career in the biotechnology industry, Mr. Connors has held leadership roles in manufacturing, product design/engineering, and corporate management.  He has Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute in Worcester, MA.

Before joining Repligen in 2015, Steve Curran was a Global Network Leader of Life Technologies/Thermo Fisher Scientific.  For the last 10 years, Mr. Curran has managed Global Genetic Analysis and Chromatography consumables operations at multiple sites around the globe, building efficient operations utilizing Lean methodologies and upgrading Quality systems.  He also led the design, construction and commissions of two multiple-product plants that meet stringent regulatory requirements.  Prior to this role, Mr. Curran worked as a Development Engineer for 15 years in the biotechnology industry at different levels of leadership, with roles including product transfer, process scale-up and validation.  He received a B.S. in Chemical Engineering from WPI in Worcester, MA.

Ken Elmer joined Repligen in November 2016. He has over 30 years of experience in the professional services industry,  IT services and technical and management consulting.  Ken has worked with high growth and entrepreneurial companies in multiple countries and in a wide variety of industries, including Manufacturing, Insurance. Financial Services, Life Sciences, Distribution and Telecommunications.  Most recently, Ken was the Chief Human Resources Officer of Attune Consulting, a global SAP service provider. Prior to that, he was with Celerant Consulting, an Operations Management consulting firm, as the Senior Vice President of Human Resources. Other previous leadership positions include Vice President of Human Resources at GlassHouse Technologies, Chief People Officer at Viant Corporation and Vice President of HR at Cambridge Technology Partners, where he held numerous line and leadership roles over nine years, including launching operations in both Ireland and Switzerland.

Before joining Repligen in 2015, Christine Gebski was Head of the POROS® Business Unit within the Bioproduction Division of Applied Biosystems/LIFE Technologies/Thermo Fisher Scientific, working with purification products, including POROS® and CaptureSelect®  chromatography resins.  She managed Global Process Chromatography Applications for ten years, developing collateral and providing technical support, supporting new product development and manufacturing process improvement efforts. She also managed R&D, developing and commercializing three new chromatography resins. Before joining LIFE Technologies, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, with roles in both development and engineering functions, including developing, scaling, transferring and validating downstream purification processes.  She received a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Rachel Goodrich joined Repligen in January 2015 as Senior Director of Marketing, and was promoted to Vice President of Marketing in March 2017.  She rebranded Repligen as a bioprocessing company, developed and launched the Repligen website, implemented high ROI tools for the commercial organization from innovative Marketing-On-Demand to targeted technical roadshows and webinars, building out an organization covering marketing communications, market research, strategic planning and digital marketing.  Prior to joining Repligen, she was Market Development Leader for the Bioproduction Division of LIFE Technologies/ Thermo Fisher Scientific/ Applied Biosystems, responsible for global market development and marketing programs for four franchise business units, and was the recipient of numerous Marketing Excellence Awards. She received a B.A. in Economics from the University of the Philippines and Masters Degrees in Economics and in Education from Stanford University.

Vikas Gupta joined Repligen in March 2016 as Vice President of Business Development and Strategy.  Prior to joining Repligen,  Mr. Gupta worked at GE Life Sciences from 2012 to 2015 in commercial leadership roles managing its Enterprise Solutions & Services business as well as the single-use and filtration portfolio.  Before GE, Mr. Gupta worked at Millipore from 2004 to 2011 in business development and product management roles,  playing an instrumental role in the early growth of its Mobius single-use bioprocessing business.  He is one of the early champions of a risk-based approach in assessing the impact of extractables and leachables, as well as sustainability initiatives for the disposal of disposables.  He received his  B.S.  in Chemical engineering and an MBA from India, and an M.S. in Finance from Bentley University in Waltham, MA.

Ralf Kuriyel joined Repligen in October 2016 as Senior Vice President of Research and Development. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation, whose acquisition by Danaher Corporation was completed in August 2015. During his 11-year tenure at Pall, Mr. Kuriyel played a key role in expanding the Global Applications R&D function to include cell culture and single-use applications, process monitoring technologies, and process development services. Prior to Pall, Mr. Kuriyel held various technology and applications development management roles within the Biopharmaceutical Division of Millipore Corporation, which was acquired by Merck KGaA in 2010. Mr. Kuriyel received his B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute, and completed coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

Martin Reuter joined Repligen in April 2016 as Vice President, Managing Director of Repligen GmbH in Weingarten, Germany, where he oversees the operations, finances and development of the German subsidiary. Mr. Reuter was previously CEO of Atoll GmbH (acquired by Repligen in April 2016), a company that developed, manufactured and distributed chromatography columns for downstream processing. Before that, Mr. Reuter spent eight years with various venture capital companies.  He was the Managing Director of a car rental company for six years, with a fleet of 4000 vehicles and 600 staff.  He began his career in the software business where he was trainer for different software packages. Mr. Reuter received a diploma in Economics at the Deutsche Hochschule (DHBW) in Ravensburg, Germany.

Gustav Silfversparre was named Vice President of Operations at Repligen in March 2013 and is managing Repligen’s manufacturing site in Lund, Sweden. Before coming to Repligen, Mr. Silfversparre was Operations Director at Novozymes Biopharma AB, which was acquired by Repligen in December 2011. Between 2008-2010, Mr. Silfversparre was Head of Biopharma Coordination, a global project and production coordination function for the biopharma area within Novozymes.From 2002 to 2008, Mr. Silfversparre was Head of the Development Department at Novozymes Biopharma AB. Mr. Silfversparre received a Tech. Lic. Biotechnology at Royal Institute of Technology and M.Sc. Chemical Engineering at the Faculty of Engineering, Lund University. 

A graduate from the University of Leeds, England, Stephen Tingley has been recognized contributor to the bioprocessing industry for over 25 years. Having worked initially for GSK, Mr. Tingley then joined Millipore creating and sharing expertise in sterile and downstream processing. At Millipore, Mr. Tingley became a recognized early champion of the development and adoption of single use technologies. He has had experience commercializing several leading technologies, including massively parallel microbioreactors system for upstream process development, multi-column chromatography and, most recently, leading the disposable chromatography team at Repligen that developed the OPUS® pre-packed column line.

BOARD OF DIRECTORS

KDawes.jpgKaren A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth, a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of positions in Marketing, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves as a Director of Symbiomix Therapeutics, LLC and Depomed, Inc. Ms. Dawes’ qualifications to sit on the Company’s Board of Directors include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business.

NBarthelemy.jpg

Nicolas M. Barthelemy has served as Director of Repligen since June 2014. Mr. Barthelemy brings over 25 years of health-care industry experience to the director role.  Prior to Biotheranostics, a molecular diagnostics company where he was President and CEO from September 2014 until February 2017,  he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy currently also serves on the boards of directors of Essen Bioscience. He received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board of Directors include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

Glenn_Cooper_photo.jpgGlenn L. Cooper, M.D. has served as a director of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. Prior to that, Dr. Cooper served as the Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on urology and endocrinology, from 2000 to 2009 and as Chief Executive Officer and Director from 1993 to 2000. Prior to joining Indevus in 1993, Dr. Cooper held numerous executive level positions including President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly and Company. Dr. Cooper has participated in the development, approval and commercialization of numerous drugs including Prozac®, Axid®, Lorabid®, Ceclor®, SANCTURA®, SANCTURA XR®, Supprelin-LA® and Vantas®. Dr. Cooper received an M.D. from Tufts University School of Medicine, performed his postdoctoral training in Internal Medicine and Infectious Diseases at the New England Deaconess Hospital and the Massachusetts General Hospital and received a B.A. from Harvard College. Dr. Cooper also serves as the Chairman of the Board of Directors of Lascaux Media, LLC, a privately held company. Dr. Cooper’s qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies.

John-Cox_Biogen.jpgJohn G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he has held since June 2010. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen’s operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003, Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. Mr. Cox received a B.S. in cell biology from California State University and a Masters of Business Administration in Finance degree from the University of Michigan. Mr. Cox’s qualifications to sit on the Company’s Board of Directors include his extensive experience of biopharmaceutical manufacturing.

TH_281x272.jpgTony J. Hunt was named President and Chief Executive Officer of Repligen in  May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management.

GMuir.jpgGlenn P. Muir has served as director of Repligen and member of its audit committee since October 2015. Mr. Muir brings over 30 years of experience to the director role, including sixteen years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President, Finance and Administration. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as CFO since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned a Masters of Science from Bentley University and a Masters of Business Administration from Harvard University. Mr. Muir also serves on the boards of medical device company ReWalk Robotics Ltd. and genomic tool company RainDance Technologies, Inc. Mr. Muir’s qualifications to sit on Repligen’s Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

Ryan-Thomas-F.jpgThomas F. Ryan Jr. has served as a director of Repligen since September 2003 and is currently a private investor. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a Director for the New York State Independent System Operator, a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.

Scroll To Top